NDA (New Drug Application)
ANDA (Generic Application)
It is formulated by 1 pharmaceutical company such as NOVARTIS. It is marketed under 1 brand name, including VANRAFIA. Available in 1 different strength, such as EQ 0.75MG BASE, and administered through 1 route including TABLET;ORAL.
Track protection status across key markets to assess launch feasibility.
API availability: Loading API feasibility...
Licensing: 1 potential partnersUS Launch window: Loading launch window...
FDA approval history for this ingredient
Key expiration dates for US patents covering this ingredient
Latest drug strengths approved by FDA
| Strength | Route of Administration | Companies | Latest Approval Date |
|---|
Patents approved by the FDA for the ingredient
|
|
Patent Number | Publication Date | Legal Status | Patent Expiry Date | |
|---|---|---|---|---|---|
| {"application_id":"164562","ingredient":"ATRASENTAN HYDROCHLORIDE","trade_name":"VANRAFIA","family_id":"","publication_number":"US8623819B2","cleaned_patent_number":"8623819","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2028-08-22","publication_date":"2014-01-07","legal_status":"Patented Case"} | US8623819B2 | 07 Jan, 2014 | Patented Case | 22 Aug, 2028 | |
| {"application_id":"164565","ingredient":"ATRASENTAN HYDROCHLORIDE","trade_name":"VANRAFIA","family_id":"3f670476332040549ebf","publication_number":"US11874283B2","cleaned_patent_number":"11874283","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2032-02-18","publication_date":"2024-01-16","legal_status":"Granted"} | US11874283B2 | 16 Jan, 2024 | Granted | 18 Feb, 2032 | |
| {"application_id":"164567","ingredient":"ATRASENTAN HYDROCHLORIDE","trade_name":"VANRAFIA","family_id":"","publication_number":"US9364458B2","cleaned_patent_number":"9364458","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-07-07","publication_date":"2016-06-14","legal_status":"Patented Case"} | US9364458B2 Formulation | 14 Jun, 2016 | Patented Case | 07 Jul, 2034 | |
| {"application_id":"164568","ingredient":"ATRASENTAN HYDROCHLORIDE","trade_name":"VANRAFIA","family_id":"","publication_number":"US10016393B2","cleaned_patent_number":"10016393","drug_product_flag":"Y","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2034-07-07","publication_date":"2018-07-10","legal_status":"Granted"} | US10016393B2 Formulation | 10 Jul, 2018 | Granted | 07 Jul, 2034 | |
| {"application_id":"164564","ingredient":"ATRASENTAN HYDROCHLORIDE","trade_name":"VANRAFIA","family_id":"15f13f75abb2484ea0e0","publication_number":"US11998526B2","cleaned_patent_number":"11998526","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-12-16","publication_date":"2024-06-04","legal_status":"Granted"} | US11998526B2 | 04 Jun, 2024 | Granted | 16 Dec, 2040 | |
| {"application_id":"164566","ingredient":"ATRASENTAN HYDROCHLORIDE","trade_name":"VANRAFIA","family_id":"15f13f75abb2484ea0e0","publication_number":"US11491137B2","cleaned_patent_number":"11491137","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-12-16","publication_date":"2022-11-08","legal_status":"Patented case"} | US11491137B2 | 08 Nov, 2022 | Patented case | 16 Dec, 2040 | |
| {"application_id":"164563","ingredient":"ATRASENTAN HYDROCHLORIDE","trade_name":"VANRAFIA","family_id":"15f13f75abb2484ea0e0","publication_number":"US12121509B2","cleaned_patent_number":"12121509","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2040-12-16","publication_date":"2024-10-22","legal_status":"Patented case"} | US12121509B2 | 22 Oct, 2024 | Patented case | 16 Dec, 2040 |
Latest clinical trials and research studies for this ingredient
| NCT ID | Title | Status | Phase | Conditions | Start Date | Completion Date |
|---|
Manufacturing Locations
No suppliers found.
Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.